Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis
Cancer ( IF 6.1 ) Pub Date : 2021-06-17 , DOI: 10.1002/cncr.33655 Koji Sasaki 1 , Hagop M Kantarjian 1 , Kiyomi Morita 1 , Nicholas J Short 1 , Marina Konopleva 1 , Nitin Jain 1 , Farhad Ravandi 1 , Guillermo Garcia-Manero 1 , Sa Wang 2 , Joseph D Khoury 2 , Jeffrey L Jorgensen 2 , Richard E Champlin 3 , Issa F Khouri 3 , Partow Kebriaei 3 , Heather M Schroeder 1 , Maria Khouri 1 , Rebecca Garris 1 , Koichi Takahashi 1 , Susan M O'Brien 4 , Elias J Jabbour 1
Cancer ( IF 6.1 ) Pub Date : 2021-06-17 , DOI: 10.1002/cncr.33655 Koji Sasaki 1 , Hagop M Kantarjian 1 , Kiyomi Morita 1 , Nicholas J Short 1 , Marina Konopleva 1 , Nitin Jain 1 , Farhad Ravandi 1 , Guillermo Garcia-Manero 1 , Sa Wang 2 , Joseph D Khoury 2 , Jeffrey L Jorgensen 2 , Richard E Champlin 3 , Issa F Khouri 3 , Partow Kebriaei 3 , Heather M Schroeder 1 , Maria Khouri 1 , Rebecca Garris 1 , Koichi Takahashi 1 , Susan M O'Brien 4 , Elias J Jabbour 1
Affiliation
The outcome of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus ofatumumab hyper-CVAD + ofatumumab (hyper-CVAD + ofatumumab) has not been compared with the outcome of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone plus ofatumumab hyper-CVAD plus rituximab (hyper-CVAD + Rituximab) in Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL) in a randomized clinical trial.
中文翻译：
超 CVAD 加奥法木单抗对比超 CVAD 加利妥昔单抗作为费城染色体阴性急性淋巴细胞白血病成人的一线治疗：倾向评分分析
尚未将超分割环磷酰胺、长春新碱、多柔比星和地塞米松加奥法木单抗 hyper-CVAD + 奥法木单抗（hyper-CVAD + 奥法木单抗）的结果与超分割环磷酰胺、长春新碱、多柔比星和地塞米松加奥法木单抗的结果进行比较 hyper-CVAD 加利妥昔单抗(hyper-CVAD + Rituximab) 在费城染色体阴性急性淋巴细胞白血病 (ALL) 中的一项随机临床试验。
更新日期：2021-08-23
中文翻译：
超 CVAD 加奥法木单抗对比超 CVAD 加利妥昔单抗作为费城染色体阴性急性淋巴细胞白血病成人的一线治疗：倾向评分分析
尚未将超分割环磷酰胺、长春新碱、多柔比星和地塞米松加奥法木单抗 hyper-CVAD + 奥法木单抗（hyper-CVAD + 奥法木单抗）的结果与超分割环磷酰胺、长春新碱、多柔比星和地塞米松加奥法木单抗的结果进行比较 hyper-CVAD 加利妥昔单抗(hyper-CVAD + Rituximab) 在费城染色体阴性急性淋巴细胞白血病 (ALL) 中的一项随机临床试验。
京公网安备 11010802027423号